SpringWorks Therapeutics, Inc. (SWTX)
Jul 1, 2025 - SWTX was delisted (reason: acquired by Merck KGaA)
46.99
0.00 (0.00%)
Inactive · Last trade price on Jun 30, 2025
SpringWorks Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for SpringWorks Therapeutics stock had an average target of $56.86, with a low estimate of $47 and a high estimate of $77.
Price Target: $56.86 (+21.00%)
Analyst Consensus: Buy
Price Target
Analyst Ratings
The average analyst rating for SpringWorks Therapeutics stock from 7 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
No data available
| Rating | Oct 2026 |
|---|---|
| Strong Buy | n/a |
| Buy | n/a |
| Hold | n/a |
| Sell | n/a |
| Strong Sell | n/a |
| Total | n/a |
Financial Forecast
Revenue This Year
334.05M
from 191.59M
Increased by 74.36%
Revenue Next Year
586.68M
from 334.05M
Increased by 75.63%
EPS This Year
-2.81
from -3.48
EPS Next Year
-1.51
from -2.81
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 417.5M | 753.1M | |||
| Avg | 334.1M | 586.7M | |||
| Low | 269.4M | 435.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 117.9% | 125.4% | |||
| Avg | 74.4% | 75.6% | |||
| Low | 40.6% | 30.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.59 | -0.23 | |||
| Avg | -2.81 | -1.51 | |||
| Low | -4.08 | -2.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |